LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma histology after failure of first-line platinum-based chemotherapy.
Checked against the public recordLast updated Feb 13, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Boehringer Ingelheim
- Interventions being studied
- Drug: docetaxel; Drug: docetaxel; Drug: placebo; Drug: nintedanib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion criteria: * Male or female patients of at least 18 years of age * Histologically confirmed, adenocarcinoma of the lung, after failure of first line platinum-based chemotherapy. Exclusion criteria: * More than one prior line of chemotherapy (i.e., 2nd or 3rd line chemotherapy) for advanced and/or metastatic (stage III B or IV NSCLC) or recurrent disease. * Patients known to be positive for activating Epidermal Growth Factor Receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation * Previous therapy with other vascular endothelial growth factor (VEGF) or VEGFR inhibitors (other than bevacizumab) or docetaxel for the treatment of NSCLC at any time * Prior monotherapy with an EGFR inhibitor except as maintenance therapy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- 1199.128.10032 Boehringer Ingelheim Investigational SiteChandler, Arizona
- 1199.128.10041 Boehringer Ingelheim Investigational SiteFayetteville, Arkansas
- 1199.128.10010 Boehringer Ingelheim Investigational SiteHighland, California
- 1199.128.10044 Boehringer Ingelheim Investigational SiteRancho Mirage, California
- 1199.128.10080 Boehringer Ingelheim Investigational SitePaducah, Kentucky
- 1199.128.10016 Boehringer Ingelheim Investigational SiteFarmington, New Mexico
- 1199.128.10013 Boehringer Ingelheim Investigational SiteMinot, North Dakota
- 1199.128.10077 Boehringer Ingelheim Investigational SiteBlacksburg, Virginia
- 1199.128.10011 Boehringer Ingelheim Investigational SiteKennewick, Washington
- 1199.128.64006 Boehringer Ingelheim Investigational SiteBatumi
- 1199.128.64001 Boehringer Ingelheim Investigational SiteTbilisi
- 1199.128.64002 Boehringer Ingelheim Investigational SiteTbilisi
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 13, 2025. Always confirm current availability with the study team.